Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Ablynx NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Ablynx NV, Medical Devices Deals, 2012 to YTD 2018 11
Ablynx NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Ablynx NV, Pharmaceuticals & Healthcare, Deal Details 14
Private Equity 14
BVF Partners Acquires Additional 1.74% Stake In Ablynx From Sofinnova 14
Partnerships 15
Ablynx Exercises Option for Licensing Agreement with Vectura 15
Ablynx Enters into Research Agreement with Genzyme 16
Ablynx Extends Agreement with Merck to Develop Therapeutic Nanobody Candidates 17
Taiwan Liposome and Ablynx Enter into Research Agreement 18
Ablynx Enters Into Agreement With Merck To Develop Therapeutic Nanobody Candidates 19
Licensing Agreements 20
Sanofi Signs Licensing Agreement with Ablynx 20
Novo Nordisk Enters into Licensing Agreement with Ablynx 21
Taisho Pharma Enters into Licensing Agreement with Ablynx 22
Ablynx Enters into Licensing Agreement with Eddingpharm for Anti-TNFa Nanobody 23
Merck Expands Licensing Agreement with Ablynx 24
Ablynx Enters Into Licensing Agreement With Eddingpharm 26
Equity Offering 28
Ablynx Raises USD2.3 Million in Private Placement of Shares up on Exercise of Warrants 28
Ablynx Raises USD1 Million in Private Placement of Shares up on Exercise of Warrants 29
Ablynx Raises USD2 Million in Private Placement of Shares up on Exercise of Warrants 30
Ablynx Completes Underwriters Exercise of Over-Allotment Option of Public Offering of ADS for USD230 Million 31
Ablynx Raises USD1.1 Million in Private Placement of Shares upon Exercise of Warrants 33
Ablynx Amends Private Placement of Shares 34
Ablynx Raises USD1.05 Million Through Exercise of Warrants 36
Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 37
Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 38
Ablynx Raises USD0.4 Million in Private Placement of Shares upon Exercise of Warrants 39
Ablynx Raises USD82.6 Million in Private Placement of Shares 40
Ablynx Raises USD0.05 Million in Private Placement of Shares upon Exercise of Warrants 42
Ablynx Raises USD1.4 Million upon Exercise of Warrants 43
Ablynx Raises USD57 Million in Private Placement of Shares 44
Ablynx Completes Private Placement Of Shares For US$1.2 Million Upon Exercise Of Warrants 46
Ablynx Completes Private Placement Of Shares For US$41 Million 47
Debt Offering 49
Ablynx Raises USD112 Million in Private Placement of 3.25% Bonds Due 2020 49
Acquisition 50
Sanofi Acquires Ablynx for USD4.85 Billion 50
Sofinnova Divests Its Stake In Ablynx For US$29.4 Million 52
Gimv And Biotech Fonds Vlaanderen Sell Remaining Stake In Ablynx 53
Gimv And Biotech Fonds Vlaanderen Sell Stake In Ablynx 54
Ablynx NV – Key Competitors 55
Ablynx NV – Key Employees 56
Ablynx NV – Locations And Subsidiaries 57
Head Office 57
Other Locations & Subsidiaries 57
Recent Developments 58
Financial Announcements 58
Feb 22, 2018: ABLYNX ANNOUNCES 2017 FULL YEAR RESULTS 58
Nov 16, 2017: Ablynx Announces Results For The First Nine Months Of 2017 And A Year-To-Date Business Update 61
Aug 24, 2017: Ablynx Announces 2017 Half Year Results and Year-to-date Business Update 63
May 11, 2017: Ablynx Reports Financial Results for the First Three Months Of 2017 and a Year-To-Date Business Update 66
Feb 23, 2017: Ablynx Announces 2016 Full Year Results 68
Corporate Communications 69
Feb 07, 2018: Ablynx Announces Resignation of Dr Bo Jesper Hansen From the Board of Directors 69
Jan 24, 2018: Ablynx Names Dr Robert Friesen as Chief Scientific Officer 70
Jan 08, 2018: Ablynx Announces Board Changes 71
Jul 17, 2017: Ablynx Proposes Appointment of Mrs Hilde Windels as a New Independent Director 72
Jun 13, 2017: Ablynx Appoints Markus Ewert As Chief Business Officer 73
Mar 07, 2017: Merck reports positive data from Phase Ib trial of M1095 in psoriasis patients 74
Clinical Trials 75
Jan 11, 2017: Ablynx Initiates Phase IIb “Respire” Study of its Inhaled Anti-RSV Nanobody, Alx-0171, For Treatment of RSV Infections In Hospitalised Infants 75
Appendix 77
Methodology 77
About GlobalData 77
Contact Us 77
Disclaimer 77
Ablynx NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Ablynx NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Ablynx NV, Deals By Therapy Area, 2012 to YTD 2018 10
Ablynx NV, Medical Devices Deals, 2012 to YTD 2018 11
Ablynx NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
BVF Partners Acquires Additional 1.74% Stake In Ablynx From Sofinnova 14
Ablynx Exercises Option for Licensing Agreement with Vectura 15
Ablynx Enters into Research Agreement with Genzyme 16
Ablynx Extends Agreement with Merck to Develop Therapeutic Nanobody Candidates 17
Taiwan Liposome and Ablynx Enter into Research Agreement 18
Ablynx Enters Into Agreement With Merck To Develop Therapeutic Nanobody Candidates 19
Sanofi Signs Licensing Agreement with Ablynx 20
Novo Nordisk Enters into Licensing Agreement with Ablynx 21
Taisho Pharma Enters into Licensing Agreement with Ablynx 22
Ablynx Enters into Licensing Agreement with Eddingpharm for Anti-TNFa Nanobody 23
Merck Expands Licensing Agreement with Ablynx 24
Ablynx Enters Into Licensing Agreement With Eddingpharm 26
Ablynx Raises USD2.3 Million in Private Placement of Shares up on Exercise of Warrants 28
Ablynx Raises USD1 Million in Private Placement of Shares up on Exercise of Warrants 29
Ablynx Raises USD2 Million in Private Placement of Shares up on Exercise of Warrants 30
Ablynx Completes Underwriters Exercise of Over-Allotment Option of Public Offering of ADS for USD230 Million 31
Ablynx Raises USD1.1 Million in Private Placement of Shares upon Exercise of Warrants 33
Ablynx Amends Private Placement of Shares 34
Ablynx Raises USD1.05 Million Through Exercise of Warrants 36
Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 37
Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 38
Ablynx Raises USD0.4 Million in Private Placement of Shares upon Exercise of Warrants 39
Ablynx Raises USD82.6 Million in Private Placement of Shares 40
Ablynx Raises USD0.05 Million in Private Placement of Shares upon Exercise of Warrants 42
Ablynx Raises USD1.4 Million upon Exercise of Warrants 43
Ablynx Raises USD57 Million in Private Placement of Shares 44
Ablynx Completes Private Placement Of Shares For US$1.2 Million Upon Exercise Of Warrants 46
Ablynx Completes Private Placement Of Shares For US$41 Million 47
Ablynx Raises USD112 Million in Private Placement of 3.25% Bonds Due 2020 49
Sanofi Acquires Ablynx for USD4.85 Billion 50
Sofinnova Divests Its Stake In Ablynx For US$29.4 Million 52
Gimv And Biotech Fonds Vlaanderen Sell Remaining Stake In Ablynx 53
Gimv And Biotech Fonds Vlaanderen Sell Stake In Ablynx 54
Ablynx NV, Key Competitors 55
Ablynx NV, Key Employees 56
Ablynx NV, Subsidiaries 57
List of Figures
Ablynx NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Ablynx NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Ablynx NV, Medical Devices Deals, 2012 to YTD 2018 11